CLINICAL TRIALS PROFILE FOR CEREZYME

All Clinical Trials for CEREZYME

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00364858 ↗	Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease	Completed	Genzyme, a Sanofi Company	Phase 4	2001-12-01	This is a multicenter, randomized trial to compare the safety and efficacy of two dosing frequencies of Cerezyme® in patients with Gaucher disease who are currently being treated with Cerezyme®. Approximately 90 patients will be randomized in a 2:1 (q4 : q2) ratio to one of two treatment arms at up to 26 study centers worldwide. Patients will continue to receive the same total 4-week dose that they were receiving prior to study enrollment, however, they will be randomized to receive either their total 4-week dose in two infusions, one infusion every 2 weeks or their total 4-week dose in one infusion every 4 weeks. The randomization scheme will ensure a 2:1 balance between the every 4-week versus every 2-week infusion groups, respectively.
NCT00365131 ↗	A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.	Completed	Genzyme, a Sanofi Company	Phase 4	1997-12-01	This is a multicenter, open-label, prospective study of the efficacy of Cerezyme in treating patients with skeletal manifestations secondary to Type I Gaucher disease. The study objective is to evaluate and quantify skeletal responses as compared to baseline in Type I gaucher disease patients receiving Cerezyme therapy for 48 months. Additional objectives were to assess the usefulness of various skeletal parameters, such as bone pain, bone crises, bone mineral density, and serum and urine bone markers, as indicative of treatment response and may be useful in dose management.
NCT00712348 ↗	Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase	Completed	Pfizer	Phase 3	2008-12-01	This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase (Cerezyme®) enzyme replacement therapy.
NCT00712348 ↗	Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase	Completed	Protalix	Phase 3	2008-12-01	This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase (Cerezyme®) enzyme replacement therapy.
NCT01136304 ↗	Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)	Completed	University of Pittsburgh		2010-04-01	With the participation of an international consortium of investigators, the investigators will evaluate the validity of a new severity score system called DS3 for adult patients with Gaucher disease. The investigators hypothesize that initial DS3 scores will be predictive of both disease progression and patterns of response including imiglucerase dose sensitivity and completeness and maintenance of response and that sequential DS3 scores will accurately portray either clinical progression of disease or improvement in response to treatment. The investigators will also collect DNA specimens that in future research will be used in conjunction with the DS3 scores to evaluate determinants of the clinical course and the response to treatments for Gaucher disease.
NCT01136304 ↗	Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)	Completed	University Research Foundation for Lysosomal Storage Diseases, Inc.		2010-04-01	With the participation of an international consortium of investigators, the investigators will evaluate the validity of a new severity score system called DS3 for adult patients with Gaucher disease. The investigators hypothesize that initial DS3 scores will be predictive of both disease progression and patterns of response including imiglucerase dose sensitivity and completeness and maintenance of response and that sequential DS3 scores will accurately portray either clinical progression of disease or improvement in response to treatment. The investigators will also collect DNA specimens that in future research will be used in conjunction with the DS3 scores to evaluate determinants of the clinical course and the response to treatments for Gaucher disease.

Clinical Trial Conditions for CEREZYME

Condition Name

Condition Name for CEREZYME
Intervention	Trials
Gaucher Disease	5
Glucosylceramide Beta-Glucosidase Deficiency Disease	2
Gaucher Disease, Non-Neuronopathic Form	2
Gaucher's Disease Type III	2

Condition MeSH

Condition MeSH for CEREZYME
Intervention	Trials
Gaucher Disease	10
Deficiency Diseases	2
Lipidoses	2

Clinical Trial Locations for CEREZYME

Trials by Country

Trials by Country for CEREZYME
Location	Trials
United States	21
United Kingdom	7
Spain	3
Canada	3
Australia	2

Trials by US State

Trials by US State for CEREZYME
Location	Trials
Florida	4
New York	2
Georgia	2
District of Columbia	1
Virginia	1

Clinical Trial Progress for CEREZYME

Clinical Trial Phase

Clinical Trial Phase for CEREZYME
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	4
Phase 2	1

Clinical Trial Status

Clinical Trial Status for CEREZYME
Clinical Trial Phase	Trials
Completed	5
Withdrawn	1
Not yet recruiting	1

Clinical Trial Sponsors for CEREZYME

Sponsor Name

Sponsor Name for CEREZYME
Sponsor	Trials
Genzyme, a Sanofi Company	4
ISU Abxis Co., Ltd.	2
Sanofi	2

Sponsor Type

Sponsor Type for CEREZYME
Sponsor	Trials
Industry	10
Other	3

Clinical Trials Update, Market Analysis, and Projection for CEREZYME

Last updated: January 26, 2026

Summary

CEREZYME (imiglucerase) is a lysosomal enzyme replacement therapy developed by Sanofi Genzyme to treat Gaucher disease type 1, a rare autosomal recessive genetic disorder characterized by deficient activity of the enzyme glucocerebrosidase. As of 2023, CEREZYME remains a cornerstone therapy within its niche but faces competitive pressures and evolving regulatory landscapes. This analysis provides an up-to-date review of clinical trials involving CEREZYME, assesses its market landscape, and projects its future performance, including potential growth areas and challenges.

---

What Are the Recent Developments in CEREZYME’s Clinical Trials?

Current Status and Ongoing Trials

CEREZYME’s development history includes extensive trials focusing on efficacy, safety, dosage optimization, and rare phenotypic variants of Gaucher disease. As of 2023, the clinical trial landscape features predominantly post-approval studies, observational registries, and real-world evidence generation.

Trial Type	Purpose	Status	Sample Size / Duration
Post-Marketing Surveillance	Long-term safety and effectiveness	Ongoing	N/A; indefinite
ERT dosing optimization	Effect of varying doses on enzyme activity and symptoms	Completed / Published	50-200 patients, 6-24 months
Pediatric efficacy studies	Safety/efficacy in children	Ongoing / Pending publication	30-60 children, 12-36 months
Real-world evidence registry	Effectiveness in routine clinical practice	Active	>1,000 patients worldwide
Novel formulations or adjunct therapies	Investigate enhanced delivery, immune responses	Preclinical / Early phases	Not available

Key Notes:

• No recent pivotal Phase III trials are currently registered, reflecting the stability of CEREZYME’s approval status.
• The focus has shifted toward long-term safety, pharmacovigilance, and expanding indications, such as in pediatric or special populations.

Recent Publications and Regulatory Updates

• The FDA and EMA continue to endorse CEREZYME’s safety profile, with routine monitoring of adverse effects reported in post-market data.
• Recent studies have explored the immunogenic response, with approximately 10-15% of patients developing anti-drug antibodies, which may impact efficacy in rare cases [2].

---

Market Analysis of CEREZYME

Market Overview and Revenue Generation

CEREZYME holds a pivotal position in the enzyme replacement therapy healthcare segment. Estimated to generate approximately $600 million in global annual sales in 2022, the market is characterized by:

Parameter	Details
Estimated Global Sales (2022)	~$600 million
Major Markets	US, EU, Japan, Canada
Market Penetration	~60% of diagnosed Gaucher patients globally
Pricing (per dose)	$100,000 - $150,000
Pricing Variability	Based on country, health insurance schemes

Key Competitive Products:

Product Name	Developer	Approval Year	Indication(s)	Market Share (Estimated, 2022)
VPRIV (velaglucerase alfa)	Takeda Pharma	2014	Gaucher disease	20-25%
Cerdelga (eliglustat)	Sanofi Genzyme	2014	Gaucher disease (oral therapy)	10-15%
Other off-label therapies	Various	N/A	Adjunct therapies, experimental	Remaining

Market Drivers

• Prevalence and Diagnosis: Estimated at 1 in 50,000 to 100,000 live births globally, but underdiagnosed [3].
• Access and Reimbursement: Increasing coverage in developed markets; reimbursement policies have adhered closely to clinical guidelines.
• Newer Technologies: Substrate reduction therapies (e.g., eliglustat) provide oral alternatives, influencing market dynamics.

Market Challenges

• High Cost: Pricing remains a barrier in lower-income regions.
• Immunogenicity: Anti-drug antibody development reduces long-term satisfaction.
• Limited Indications: Currently approved only for Gaucher disease type 1; expansion into related lysosomal storage disorders remains uncertain.

---

Market Projection and Future Outlook

Forecasting Methodology

Forecast models incorporate:

• Historical sales data.
• Epidemiological estimates.
• Competitive landscape.
• Regulatory and technological developments.
• Potential pipeline expansion or formulary restrictions.

Forecast period: 2023–2033.

Parameter	Projection (2023-2033)
Compound Annual Growth Rate (CAGR)	3-5% globally
Estimated 2033 Revenue	~$770 million - $900 million (assuming stable or slightly growing market)
Key Growth Areas	Emerging markets, pediatric indications, combination therapies

Potential Growth Drivers

• Pipeline Assets: Development of supportive therapies, such as chaperones or gene therapies, could complement or eventually replace ERTs.
• Expanded Indications: Trials exploring use for other Gaucher variants and related lysosomal storage disorders.
• New Formulations: Subcutaneous or longer-acting formulations under clinical evaluation may enhance adherence and expand patient base.

Market Risks and Limitations

• Entry of Biosimilars: Patent expirations possible by 2025, potentially curbing revenue unless patent extensions are secured.
• Regulatory Changes: Stricter reimbursement policies or approval barriers for new formulations.
• Genetic Screening: Growing early diagnosis may increase initial treatment rates but also pressure pricing.

---

Comparison with Competitors and Alternatives

Aspect	CEREZYME	VPRIV	Cerdelga	Emerging Therapies
Type	Recombinant enzyme	Recombinant enzyme	Oral substrate reduction therapy	Gene therapy, pharmacological chaperones
Approval Year	1994 (original)	2014	2014	2020s
Administration	IV infusion	IV infusion	Oral	Gene therapy (experimental)
Market Share (2022)	~60%	20-25%	10-15%	N/A
Cost per Treatment	$150,000 (annual approx.)	Similar to CEREZYME	Significantly lower (per year)	Varies, often higher initial costs
Key Strengths	Proven efficacy, longstanding use	Similar efficacy, shorter infusion	Oral, improved convenience	Potentially curative, less invasive

---

Regulatory and Policy Environment

• FDA and EMA: Continuing to endorse CEREZYME based on registry data, with routine pharmacovigilance.
• Pricing Policies: Managed access agreements and risk-sharing schemes influence market penetration.
• Orphan Drug Status: Maintained in major markets, providing market exclusivity until approximately 2027-2029.

---

Key Takeaways

1. Clinical Development: CEREZYME’s clinical trials predominantly focus on safety monitoring and expanding pediatric use; no recent pivotal trials suggest a stable efficacy profile.
2. Market Position: Despite competition, CEREZYME remains the dominant therapy for Gaucher disease type 1, with steady sales driven by targeted patient populations.
3. Growth Opportunities: Emerging market expansion, long-acting formulations, and potential new indications could bolster revenue.
4. Challenges: Patent expiries, biosimilar threats, and the rise of oral therapies pose risks to future market share.
5. Strategic Focus: Innovation in delivery methods, combination therapy research, and regulatory engagement are crucial for maintaining leadership.

---

FAQs

1. What is the current clinical trial landscape for CEREZYME?
Most ongoing studies focus on long-term safety, pediatric efficacy, and real-world effectiveness. No large-scale Phase III trials are active, indicating stability in its clinical profile.

2. How does CEREZYME compare to alternative therapies?
CEREZYME remains the gold standard for enzyme replacement therapy, with proven efficacy. Alternatives like VPRIV offer similar benefits, while oral treatments such as Cerdelga provide convenience but may differ in long-term outcomes.

3. What are the prospects for CEREZYME’s future market growth?
Projected CAGR of 3-5% through 2033 driven by geographic expansion, unique formulations, and potential label expansions; however, biosimilars and pipeline competition could impact this.

4. Are there new developments that could replace CEREZYME?
Gene therapies and pharmacological chaperones are under investigation and may, in the future, offer curative or less invasive options.

5. How do patent and regulatory policies influence CEREZYME’s market outlook?
Patent exclusivity is expected to expire around 2027-2029; regulatory agencies continue to support orphan drug designations, but market access negotiations and healthcare policies may influence revenue trajectories.

---

References

[1] Sanofi Genzyme. CEREZYME product information. 2023.
[2] Beutler E, Kallish S, Grabowski GA. Enzyme replacement therapy for Gaucher disease. N Engl J Med. 2003;348(1):66-73.
[3] Grabowski GA. Gaucher disease and other storage disorders. Hematology Am Soc Hematol Educ Program. 2008;2008(1):422-426.